According to medical professionals and scientists, there might be a connection between a brain-gut and irritable bowel syndrome. This syndrome might be caused by anxiety and depression constantly fueling one another. But there’s a solution to this problem. The solution is a marijuana-infused chewing gum.
According to U.S. statistics, more than 3.5 million Americans suffer from irritable bowel syndrome.
This revolutionary gym was produced by an American marijuana company, and as Dutch specialists explain that it has the potential to cure IBS.
Some older studies have proved that the cannabidiol, a non-psychoactive cannabinoid CBD, could effectively treat irritable bowel syndrome due to its anti-inflammatory properties. So, the development of this cannabinoid-derived pharmaceutical intended for the treatment of IBS should come as no surprise.
Dutch medical researchers from Wageningen University and Research Centre will start testing this “CanChew” marijuana-infused chewing gum that was produced by the company which is famous for selling hemp-derived CBD oil – Medical Marijuana, Inc. in San Diego, California.
Until today, experts haven’t found a cure for irritable bowel syndrome, so the laboratory tests for this CBD-infused gum are expected to be the first of this kind.
Cannabidiol is powerful enough to reduce the frequency and severity of colon spasm in people who suffer from IBS. The reduced pressure in the digestive tract will reduce cramping and bloating, which will allow bowel movements in irritable bowel syndrome patients.
This gum contains 50 mg of cannabidiol. Scientists will test the gum on 40 volunteers with IBS, at the ages between 18 and 65. One group will take up to 6 gums every day, while other a placebo.
AXIM ® Biotechnologies, Inc. considers this marijuana-infused chewing gum will be effective in treating colitis, Crohn’s disease, and other GI conditions. This will help a lot of people who experience terrible symptoms, especially Crohn’s disease patients.
AXIM explains that if the gum gives positive results in this study, they will proceed to the second round of clinical trials as soon as possible. But, it’s still unknown when this innovative product will arrive in America and into the hands of IBS sufferers.